NASDAQ:BBLG Bone Biologics (BBLG) Stock Price, News & Analysis $1.24 -0.02 (-1.59%) Closing price 04:00 PM EasternExtended Trading$1.27 +0.03 (+2.74%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Bone Biologics Stock (NASDAQ:BBLG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bone Biologics alerts:Sign Up Key Stats Today's Range$1.21▼$1.2750-Day Range$1.08▼$1.4052-Week Range$1.05▼$6.75Volume32,902 shsAverage Volume10,620 shsMarket Capitalization$2.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Bone Biologics, Inc. (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells. Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects. Early-stage clinical studies and preclinical investigations are underway to assess safety, tolerability and preliminary efficacy in these high-need segments. The company collaborates with leading orthopedic surgeons and academic centers to design protocols and gather real-world insights that may inform future pivotal trials. Founded in the late 2010s and headquartered in New Jersey, Bone Biologics has assembled a leadership team with extensive experience in regenerative medicine, cell therapy manufacturing and orthopedic clinical development. The company maintains partnerships with contract development and manufacturing organizations to scale its cell production processes, while engaging regulatory consultants to support filings with health authorities. As a dedicated cell therapy innovator, Bone Biologics aims to address significant unmet needs in bone repair and establish new standards for patient outcomes in orthopedic care.AI Generated. May Contain Errors. Read More Bone Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreBBLG MarketRank™: Bone Biologics scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBone Biologics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBone Biologics has only been the subject of 1 research reports in the past 90 days.Read more about Bone Biologics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Bone Biologics are expected to grow in the coming year, from ($1.52) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bone Biologics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bone Biologics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBone Biologics has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bone Biologics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.17% of the float of Bone Biologics has been sold short.Short Interest Ratio / Days to CoverBone Biologics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bone Biologics has recently decreased by 72.22%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBone Biologics does not currently pay a dividend.Dividend GrowthBone Biologics does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentBone Biologics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Bone Biologics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for BBLG on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.MarketBeat Follows1 people have added Bone Biologics to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bone Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders7.50% of the stock of Bone Biologics is held by insiders.Percentage Held by Institutions34.30% of the stock of Bone Biologics is held by institutions.Read more about Bone Biologics' insider trading history. Receive BBLG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bone Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBLG Stock News HeadlinesBone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1May 19, 2026 | globenewswire.comBBLG in good shape as critical tests underwayMay 15, 2026 | msn.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.May 27 at 1:00 AM | Weiss Ratings (Ad)BBLG Approaching Crucial StageFebruary 25, 2026 | finance.yahoo.comBone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 OutlookJanuary 8, 2026 | globenewswire.comBone Biologics stock rises after extending product shelf lifeDecember 23, 2025 | investing.comBone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 MonthsDecember 23, 2025 | globenewswire.comBBLG Has Cash for Approval PushNovember 17, 2025 | msn.comSee More Headlines BBLG Stock Analysis - Frequently Asked Questions How have BBLG shares performed this year? Bone Biologics' stock was trading at $1.45 at the start of the year. Since then, BBLG shares have decreased by 14.5% and is now trading at $1.24. How were Bone Biologics' earnings last quarter? Bone Biologics Corp. (NASDAQ:BBLG) released its earnings results on Thursday, May, 14th. The company reported ($0.43) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.43). When did Bone Biologics' stock split? Shares of Bone Biologics reverse split on the morning of Tuesday, June 10th 2025.The 1-6 reverse split was announced on Monday, June 9th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 9th 2025. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. When did Bone Biologics IPO? Bone Biologics (BBLG) raised $8 million in an initial public offering on Wednesday, October 13th 2021. The company issued 1,510,455 shares at a price of $5.25 per share. How do I buy shares of Bone Biologics? Shares of BBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bone Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bone Biologics investors own include Pfizer (PFE), NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), Advanced Micro Devices (AMD), Canopy Growth (CGC) and Cisco Systems (CSCO). Company Calendar Last Earnings5/14/2026Today5/27/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BBLG's financial health is in the Red zone, according to TradeSmith. BBLG has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolNASDAQ:BBLG Previous SymbolNASDAQ:BBLG CIK1419554 Webwww.bonebiologics.com Phone781-552-4452FaxN/AEmployees2Year Founded2004Profitability EPS (Trailing Twelve Months)($2.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.11 million Net MarginsN/A Pretax MarginN/A Return on Equity-50.47% Return on Assets-47.40% Debt Debt-to-Equity RatioN/A Current Ratio16.11 Quick Ratio16.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.60 per share Price / Book0.48Miscellaneous Outstanding Shares1,800,000Free Float1,686,000Market Cap$2.23 million OptionableNot Optionable Beta0.89 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:BBLG) was last updated on 5/27/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bone Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
